PARIS--(BUSINESS WIRE)--Theranexus, a biopharmaceutical company already in the clinical trial
stages of its lead project, has announced the publication of an article
in Sleep1, a peer-reviewed journal and a recognised
international reference point for research into sleep disorders.
For Theranexus, who discover and develop innovative drug combinations that use the modulation of glial connexin activity to improve the effectiveness and tolerance of certain neurological and psychiatric treatments, this publication validates the preclinical results obtained for its product THN102 in the treatment of narcolepsy (a rare and particularly incapacitating medical condition involving the unpredictable onset of sleep throughout the course of the day).
Very encouraging preclinical results
THN102 is a combination of two products already administered to humans but never at the same time, flecainide (an antiarrhythmic agent used in this instance at very low dosages and for its modulating effects on the glial connexins) and modafinil, an established wakefulness-promoting agent.
This article describes the pharmacological properties of the product THN102 and presents data regarding its mechanism of action. These preclinical results, obtained from models relating to the disease, have made it possible to prove that in comparison with the reference agent, modafinil, the combination proposed by Theranexus presents superior results on criteria regarding wakefulness, cognition and a reduction in the number of episodes of sudden onset of sleep.
"This first publication in a journal such as Sleep constitutes real recognition by our peers of the interest of THN102 in the fight against somnolence. This is a great opportunity to demonstrate how the connexins, small proteins involved in the communication between cells, are a new and particularly interesting target to improve the profile of modafinil" states Mathieu Charvériat, Scientific Director of Theranexus. "Theranexus' innovation and the preclinical results obtained are very encouraging, and once confirmed in humans, could provide real hope for the improved treatment of narcolepsy" states Professor Yves Dauvilliers, National Narcolepsy Reference Centre and co-author of the study.
A product entering phase II in narcolepsy
"Alongside this publication, we have also completed our first clinical study on the effectiveness of THN102 (phase Ib) for which the results will be released between now and Summer 2016." confirms Franck Mouthon, President of Theranexus. "I am delighted to announce that the product is currently entering phase II for administration to patients suffering with narcolepsy" he concludes.
Founded in 2013, Theranexus is a biopharmaceutical company formed from a spin-off of CEA - an institution recently recognized as the most innovative research body in the world ( as per ranking in Reuters' Top 25 Global Innovators). Theranexus discovers and develops drug combinations with the objective of improving the effectiveness and tolerance of established neurological and psychiatric treatments through the combination’s modulating effects on the glial connexins.
The Theranexus science offers a unique opportunity: accelerated clinical development with a lower risk of project failure in high potential CNS indications where authorized and established treatments have problems either with tolerance and effectiveness, or with life-cycle management in relation to patent expiries. This has enabled the company to raise 3.6 million Euros in seed money from Auriga Partners, Emergence Innovations (Sofimac Partners), CEA Investissement and Rhône-Alpes Création.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.